{"ticker": {"uuid": "f011a7b2-0cf2-4b64-97d7-c1dab4c28d1c", "symbol": "PVLA", "name": "Palvella Therapeutics, Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Palvella Therapeutics (PVLA) Sees Significant Decline", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxQbnlZN1ZLZVJaNjc4MUJrQUNuRHBDd1dXV0hWeVNOS29kb2xlSk5yMzFNSURTWEZONUhFZDRlaHNDOC1rZVBOV3hRU1NsS0xmVDJqZ2N5V21tSFBXUFh0M3lxcmE4Y0J4dnZTYVBjZkkzMDNmMC1La2lHaHlQQmtVVmVzN2ZfTzBZZW1DaWY4c3FaeTYx?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-20T14:40:08+00:00", "published_display": "20 Jul 2026 14:40", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Therapeutics (PVLA) COO exercises options, then sells 4,302 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNQUsxSl9SSXFFVkd0VW9Bd1FpaHZxUGlmYVdUbDR3SGx6T3RvZHRiZlVMNjdNSFFwazBvV09lbllTZ2hxR3o1Y1lBTkd4ZmI4YnJVZWU3ZkxkMHRDYkFINTc1V2JyX2laQy1XcmRsMGRUV2dQdnpNc0dQc3ltM08zWExmTFZYQ2lscVhkWEw1elR5R29laFRMaGE0X1RtN281dGZrU09nS1Z0RG1HQVZCdDFOb3dGMlIzbElR?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-17T20:05:56+00:00", "published_display": "17 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] PALVELLA THERAPEUTICS, INC. Insider Trading Activity", "summary": "Palvella Therapeutics, Inc.'s Chief Operating Officer, Kathleen Goin, reported exercising and selling 4,302 shares of common stock on July 15, 2026, through a pre-arranged Rule 10b5-1 trading plan. The sales occurred across four transactions at weighted average prices ranging fro", "url": "https://www.stocktitan.net/sec-filings/PVLA/form-4-palvella-therapeutics-inc-insider-trading-activity-43697412446d.html", "source_name": "Stock Titan", "published_at": "2026-07-17T19:40:27", "published_display": "17 Jul 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Palvella Therapeutics (PVLA) Submits Initial Module of NDA For QTORIN", "summary": "Palvella Therapeutics (PVLA) has submitted the initial module of its New Drug Application (NDA) to the FDA for QTORIN 3.9% rapamycin anhydrous gel, a treatment for microcystic lymphatic malformations. The company plans to complete the NDA application in the latter half of 2026 an", "url": "https://finance.yahoo.com/healthcare/articles/palvella-therapeutics-pvla-submits-initial-140151901.html", "source_name": "Market source", "published_at": "2026-07-15T13:01:00", "published_display": "15 Jul 2026 13:01", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Therapeutics posts corporate presentation highlighting Phase 3 SELVA wins, NDA rolling review and $262M cash", "summary": "Palvella Therapeutics recently released a corporate presentation detailing positive Phase 3 SELVA results and plans for a potential U.S. launch of QTORIN\u2122 rapamycin for microcystic LMs in the first half of 2027. The company has a strong financial position with $262 million cash a", "url": "https://www.tradingview.com/news/tradingview:5f24f58bec376:0-palvella-therapeutics-posts-corporate-presentation-highlighting-phase-3-selva-wins-nda-rolling-review-and-262m-cash/", "source_name": "TradingView", "published_at": "2026-07-15T10:10:42", "published_display": "15 Jul 2026 10:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Palvella Therapeutics (PVLA) Proxy filing Summary", "summary": "Palvella Therapeutics (PVLA) has released a summary of its proxy filing for its annual meeting scheduled for June 10, 2026. Key voting matters include the election of three Class III director nominees, the ratification of Ernst & Young as the independent public accounting firm, a", "url": "https://quartr.com/events/palvella-therapeutics-pvla-proxy-filing_F6m87FdS", "source_name": "Quartr", "published_at": "2026-07-11T07:40:19", "published_display": "11 Jul 2026 07:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Palvella Therapeutics, Inc. \u2013 NASDAQ:PVLA", "summary": "This article provides financial information for Palvella Therapeutics, Inc. (NASDAQ: PVLA), specifically focusing on its price-to-book forward metric. It mentions that market data is provided by ICE Data Services and FactSet, with SEC filings from Quartr. The content appears to b", "url": "https://www.tradingview.com/symbols/NASDAQ-PVLA/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T18:40:21", "published_display": "04 Jul 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors", "summary": "Palvella Therapeutics has announced the appointment of Matt Pauls, J.D., M.B.A., to its Board of Directors. Pauls brings over 25 years of experience in the biopharmaceutical industry, particularly in advancing and commercializing therapies for rare diseases. This appointment come", "url": "https://finance.yahoo.com/healthcare/articles/palvella-therapeutics-appoints-accomplished-rare-113000906.html", "source_name": "Market source", "published_at": "2026-07-04T08:39:22", "published_display": "04 Jul 2026 08:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PVLA - Palvella Therapeutics Inc Volatility & Greeks", "summary": "This article provides a detailed financial overview for Palvella Therapeutics Inc (PVLA), including its last close price, market capitalization, income, sales, and various financial ratios. It also covers performance metrics such as volatility, short interest, analyst recommendat", "url": "https://finviz.com/stock?t=PVLA&ta=1&p=m&ty=ocv&b=2&r=max&ov=chain_strike&s=160", "source_name": "Finviz", "published_at": "2026-07-03T11:10:00", "published_display": "03 Jul 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Therapeutics Adds Industry Veteran to Board", "summary": "Palvella Therapeutics has expanded its Board of Directors by appointing Matthew Pauls, an industry veteran with extensive experience in biopharmaceuticals and rare diseases, as a Class I director. Pauls brings expertise in commercialization, clinical development, and M&A, which i", "url": "https://www.theglobeandmail.com/investing/markets/stocks/PVLA-Q/pressreleases/3075067/palvella-therapeutics-adds-industry-veteran-to-board/", "source_name": "The Globe and Mail", "published_at": "2026-07-02T08:11:31", "published_display": "02 Jul 2026 08:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mizuho Securities Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $240", "summary": "Mizuho Securities has reiterated its Buy rating on Palvella Therapeutics (PVLA.US), maintaining a target price of $240. This indicates a continued positive outlook from the firm regarding the company's stock performance.", "url": "https://www.moomoo.com/news/post/72327093/mizuho-securities-maintains-palvella-therapeutics-pvlaus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-07-02T06:10:00", "published_display": "02 Jul 2026 06:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Therapeutics appoints Matt Pauls to board of directors", "summary": "Palvella Therapeutics has announced the appointment of Matt Pauls to its board of directors, leveraging his 25 years of biopharmaceutical industry experience. Pauls previously held leadership roles at Savara Inc., Strongbridge Biopharma plc, and Insmed Incorporated, and served on", "url": "https://www.investing.com/news/company-news/palvella-therapeutics-appoints-matt-pauls-to-board-of-directors-93CH-4767579", "source_name": "Investing.com", "published_at": "2026-06-30T12:09:00", "published_display": "30 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Therapeutics appoints Matt Pauls to board of directors By Investing.com", "summary": "Palvella Therapeutics has appointed Matt Pauls to its board of directors, leveraging his 25 years of biopharmaceutical industry experience. Pauls, currently chair and CEO of Savara Inc., previously led Strongbridge Biopharma through its Nasdaq IPO and commercialized key therapies", "url": "https://ng.investing.com/news/stock-market-news/palvella-therapeutics-appoints-matt-pauls-to-board-of-directors-93CH-2579864", "source_name": "Investing.com Nigeria", "published_at": "2026-06-30T11:40:20", "published_display": "30 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Therapeutics stock hits 52-week high at 151.36 USD", "summary": "Palvella Therapeutics Inc. (PVLA) has reached a new 52-week high of $151.36, reflecting a 569.92% increase over the past year. Despite its $2.17 billion market capitalization, InvestingPro suggests the stock may be overvalued, although it shows strong momentum. The company recent", "url": "https://www.investing.com/news/company-news/palvella-therapeutics-stock-hits-52week-high-at-15136-usd-93CH-4766063", "source_name": "Investing.com", "published_at": "2026-06-29T20:39:44", "published_display": "29 Jun 2026 20:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella submits FDA NDA for QTORIN gel", "summary": "Palvella Therapeutics (NASDAQ:PVLA) has submitted the first module of its rolling New Drug Application (NDA) to the FDA for QTORIN 3.9% rapamycin gel. This treatment is for microcystic lymphatic malformations, a rare condition affecting over 30,000 patients in the U.S. The compan", "url": "https://grafa.com/en/news/united-states/palvella-qtorin-rapamycin-gel-fda-nda-submission", "source_name": "grafa.com", "published_at": "2026-06-29T17:26:00", "published_display": "29 Jun 2026 17:26", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN\u2122 Rapamycin for the Treatment of Microcystic Lymphatic Malformations", "summary": "Palvella Therapeutics has submitted the first module of its rolling New Drug Application (NDA) to the FDA for QTORIN\u2122 rapamycin, aimed at treating microcystic lymphatic malformations (microcystic LMs). The company expects to complete the NDA submission in the second half of 2026 ", "url": "https://uk.finance.yahoo.com/news/palvella-therapeutics-submits-first-module-113000891.html", "source_name": "Market source", "published_at": "2026-06-29T11:12:43", "published_display": "29 Jun 2026 11:12", "sentiment": "positive", "sentiment_pct": 71, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Therapeutics Submits First Rolling NDA Module for QTORIN Rapamycin in Microcystic Lymphatic Malformations", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxOb0p2UzZFWE5LTGtZZUdXeEJSdlZKY0hZZkNweEVBd1lrVGpyLUFWbXpRamdrTHVOOEQxX0hoWlhqRGtRSi1sZjdFYjhzN2tkMUNsQTVxdm9XNnc3Skx1T0RwUUFtQTY0VFFRc3NLc3FNTHdtOUJmYkhhcEhldTF3aGRYTlhWRWRfNlpBa3F0WE9xdWYxUU1vVWVXWDdqdnV5NVNocl9BWjQtS0MxLWVEc05LX2NpMEZBUmRyT21maDZZUmc3ZGRkTWl0dFZKcDZGdGpOS3VUXzF6Q19pblMxUw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What to Know About This $476,000 Palvella Therapeutics Insider Sale After a 620% Stock Rally", "summary": "", "url": "https://finance.yahoo.com/m/734dcfb8-e453-35d9-a1cd-ebde9185c0a0/what-to-know-about-this.html", "source_name": "Motley Fool", "published_at": "2026-06-27T16:31:54+00:00", "published_display": "27 Jun 2026 16:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PVLA - Palvella Therapeutics Inc Short Interest", "summary": "This article provides comprehensive financial data for Palvella Therapeutics Inc (PVLA), including its short interest, market capitalization, earnings, sales figures, and various financial ratios. It also details insider and institutional ownership, performance metrics across dif", "url": "https://finviz.com/stock?t=PVLA&ty=si&ta=1&p=d", "source_name": "Finviz", "published_at": "2026-06-26T16:40:20", "published_display": "26 Jun 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Palvella Therapeutics, Inc. \u2013 NASDAQ:PVLA", "summary": "This article provides limited information on the \"Price to earnings forward\" metric for Palvella Therapeutics, Inc. (NASDAQ: PVLA), indicating a period value, change, and percentage change. The content, which appears to be from TradingView, does not include actual financial figur", "url": "https://www.tradingview.com/symbols/NASDAQ-PVLA/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T13:40:40", "published_display": "26 Jun 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Therapeutics, Inc. Actuals & Estimates (NASDAQ:PVLA)", "summary": "This article provides an overview of Palvella Therapeutics, Inc. (PVLA) stock performance, financial actuals, and analyst estimates. Key information includes the current stock price, historical highs and lows, market capitalization, upcoming earnings reports, and revenue and net ", "url": "https://www.tradingview.com/symbols/NASDAQ-PVLA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T12:40:02", "published_display": "26 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Palvella Therapeutics, Inc. \u2013 NASDAQ:PVLA", "summary": "The article discusses the enterprise value to EBIT forward for Palvella Therapeutics, Inc. (NASDAQ: PVLA). It appears to be a stub or a section from a larger financial analysis platform, providing a title and indicating that the content would detail this financial metric. The pla", "url": "https://www.tradingview.com/symbols/NASDAQ-PVLA/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T00:39:29", "published_display": "26 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Therapeutics, Inc. Actuals & Estimates (LS:A40RA6)", "summary": "This article provides financial actuals and estimates for Palvella Therapeutics, Inc. (LS:A40RA6), including analyst opinions, historical price data, volatility, market capitalization, and upcoming earnings dates. It highlights that analysts estimate A40RA6's price to range from ", "url": "https://www.tradingview.com/symbols/LS-A40RA6/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T18:39:29", "published_display": "25 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Therapeutics Insiders Placed Bullish Bets Worth US$850.0k", "summary": "The article reports that insiders at Palvella Therapeutics recently made bullish investments, purchasing shares valued at US$850,000. These significant insider buys often signal confidence in the company's future prospects and are closely watched by investors as a potential indic", "url": "https://www.moomoo.com/news/post/72041442/palvella-therapeutics-insiders-placed-bullish-bets-worth-us-850-0k", "source_name": "Moomoo", "published_at": "2026-06-25T14:40:03", "published_display": "25 Jun 2026 14:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Palvella Therapeutics, Inc. \u2013 LS:A40RA6", "summary": "This article provides financial information for Palvella Therapeutics, Inc. (A40RA6) on TradingView. It shows that the market is closed with no trades and displays the \"Price to earnings forward\" value and period. The content is primarily a data page rather than a descriptive art", "url": "https://www.tradingview.com/symbols/LS-A40RA6/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T14:39:29", "published_display": "25 Jun 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CCORF Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $227", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNVWstZ2x4VW11ak9mM0ZHc1VjaWFsZE1mS2EzMjJWdmxnRHd6aHJsOFFuc1RZbWIzWnB5enhPMnl2ZGVzd2VkajBkY2lVRUR5a2ZrR2JEY253R2luVlFDNTJXX0lVR2xqOWdfb3piM1VJMDBfSGF6a1dOb0c2dUZIbnc4S19KMkVVTVRhOHZTZkZFa2VHdUtJa0h6VVdFOHhra0pId055TXJVanNVYWdCRmhSWWhZOVZlWTYw?oc=5", "source_name": "Moomoo", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Palvella Therapeutics, Inc. \u2013 NASDAQ:PVLA", "summary": "This article provides the \"Price to sales forward\" metric for Palvella Therapeutics, Inc. (NASDAQ: PVLA). It appears to be a financial data snippet from TradingView, offering a specific valuation ratio for the company without additional commentary or analysis. The content primari", "url": "https://www.tradingview.com/symbols/NASDAQ-PVLA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-24T15:09:29", "published_display": "24 Jun 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Palvella Therapeutics, Inc. \u2013 LS:A40RA6", "summary": "This article provides financial information for Palvella Therapeutics, Inc. (A40RA6) on TradingView, specifically focusing on its forward price-to-book value. It details the company's financial overview, news, and community discussions, all hosted on the TradingView platform whic", "url": "https://www.tradingview.com/symbols/LS-A40RA6/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-24T14:09:29", "published_display": "24 Jun 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Therapeutics COO Kathleen Goin sells $476,372 in stock By Investing.com", "summary": "Kathleen Goin, COO of Palvella Therapeutics (NASDAQ:PVLA), sold 4,302 shares worth $476,372 on June 17, 2026. This sale followed the acquisition of shares through stock option exercises valued at $34,883 and was executed under a Rule 10b5-1 trading plan. Despite the sale, the sto", "url": "https://za.investing.com/news/stock-market-news/palvella-therapeutics-coo-kathleen-goin-sells-476372-in-stock-93CH-4338777", "source_name": "Investing.com South Africa", "published_at": "2026-06-23T02:40:40", "published_display": "23 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Therapeutics COO Kathleen Goin sells $476,372 in stock", "summary": "Kathleen Goin, COO of Palvella Therapeutics (NASDAQ:PVLA), sold 4,302 shares of PVLA stock valued at $476,372 on June 17, 2026, after exercising stock options worth $34,883. The transactions were conducted under a Rule 10b5-1 trading plan. Following the sales, Ms. Goin holds no d", "url": "https://www.investing.com/news/insider-trading-news/palvella-therapeutics-coo-kathleen-goin-sells-476372-in-stock-93CH-4754022", "source_name": "Investing.com", "published_at": "2026-06-22T21:10:12", "published_display": "22 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Therapeutics granted FDA rolling review for QTORIN", "summary": "The FDA has granted Palvella Therapeutics a rolling review for its rare genetic disease drug candidate, QTORIN rapamycin. This treatment targets microcystic lymphatic malformations, a condition affecting approximately 30,000 individuals in the US with no other approved therapies.", "url": "https://grafa.com/en/news/united-states/palvella-therapeutics-qtorin-fda-rolling-review", "source_name": "grafa.com", "published_at": "2026-06-22T16:10:12", "published_display": "22 Jun 2026 16:10", "sentiment": "positive", "sentiment_pct": 86, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella shares advance after FDA grants rolling review for rare disease therapy", "summary": "Palvella shares are advancing after the FDA granted a rolling review for its rare disease therapy. A rolling review allows a drug company to submit sections of its New Drug Application (NDA) to the FDA as they are completed, rather than waiting for all sections to be finalized. T", "url": "https://www.msn.com/en-us/health/other/palvella-shares-advance-after-fda-grants-rolling-review-for-rare-disease-therapy/ar-AA26g2s9", "source_name": "MSN", "published_at": "2026-06-22T14:12:05", "published_display": "22 Jun 2026 14:12", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Therapeutics' Qtorin Granted FDA Rolling Review; Shares Rise Pre-Bell", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/palvella-therapeutics-apos-qtorin-granted-122601831.html", "source_name": "MT Newswires", "published_at": "2026-06-22T12:26:01+00:00", "published_display": "22 Jun 2026 12:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Grants Rolling Review of Palvella\u2019s QTORIN\u2122 Rapamycin NDA for Microcystic Lymphatic Malformations", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/fda-grants-rolling-review-palvella-113000180.html", "source_name": "GlobeNewswire", "published_at": "2026-06-22T11:30:00+00:00", "published_display": "22 Jun 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is Palvella Therapeutics stock rallying today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPZ1VObkxNcFdRMkpOWXFYalBXNTNkWDRCV2hGR0sxR2VaWjYtVkhLdzM1SHlKUG1KMmdTUDBBLWVXUU91MmJkUFFxNDVUWjQ3dHYzRnlFX1V2Z3N2dDZtZFN4SmYwNXA4OHJfSVk5S3UzZ0RLRWl0RWpqc2hVZ0h0RG9jdWs4anlqY1hkMld1S1k5b3NwWFZVMHhUQjhYTG94SEFGLTNySERVWUhwaTdnVQ?oc=5", "source_name": "Investing.com", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Therapeutics Announces FDA Rolling Review for QTORIN Rapamycin NDA in Microcystic Lymphatic Malformations", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxOeVdvdVlFcm9CT1ZjZXdRWVdMMnJiNVFteFdLeERScjJ6ZGNXX2phRlBfN0V3OENMM2FadUVMSjhfV2Y0VXlmaE1MZkxiRlpDa1lBMW1UUm1Sd3l4MDJxTGlxNUV3T0R5aHJXNlFhNTRkOWd2eXlMbXcxU00yWVIyZkoxUlJRdDB5LUlyRVFxbENvcXQ5bTNuT0FvcjNEZ3ZOVWliNmRreWFST2M4aEFGZmV1NkpqRXQ0TTBrT3dYTWRWdWVaMHd5eE1nU2dVYUJDZzFxU29oWWM3ZDZ0R2pXQw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Therapeutics (PVLA) Stock Valuation Check After Strong Recent Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPbFpaanNtVUFNU0ZFWlFOV0F5bWVaQTQycnd6SHJEaFNRaElOTVJYZ1l5ajItLW5kSVRENnJwMTI2UWp6WVVYRGVxMVdYNlJCVmNCREg5VXVCSkE5VHlzYVpqcDc5VzZFWVJiOFRUMk9WYkJPejE5MVpaaHVsQTlSNXYyVjRNeVJVWlpXUy0tblRwV3ZhbzRuQUpuRFM2cUdXSTBaRXJoTFVaNFE?oc=5", "source_name": "Market source", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Palvella Therapeutics (PVLA) Valuation After A Strong 1-Year Run And Recent Share Price Pullback", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Therapeutics: Qtorin Continues Making Progress, So I Remain Bullish", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQVEF2OV82U29kS3drYjU4NXdJZ3hXeEdhZlBPWF9YT2R0Y0FEWTVIRmtkWDNRbm1YQjZYTDJzVGtjN0NOZXE3cm1xWHdWdUpQQ1VMTFBPMlBVY2xUS1dLZHdkZkdMMGhnNklHWUo1RDhTSE1aRjM3Qms3amROaENQX2ZXZjAtQVNJVUNIX3ljUXdNblBxZXdnakJsOThKZzJyVzJ0bEJFZVZBc0JP?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Therapeutics Says No Additional Efficacy Study Planned for Qtorin Rapamycin", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/palvella-therapeutics-says-no-additional-121708814.html", "source_name": "MT Newswires", "published_at": "2026-06-03T12:17:08+00:00", "published_display": "03 Jun 2026 12:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN\u2122 Rapamycin in Microcystic Lymphatic Malformations", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/palvella-therapeutics-announces-completion-fda-113000899.html", "source_name": "GlobeNewswire", "published_at": "2026-06-03T11:30:00+00:00", "published_display": "03 Jun 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Prognosis For Palvella Therapeutics (NASDAQ:PVLA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxQd0hNNDBUdE5SZ2NXU2lMcjItOHdqYlhBMGdqLWItM0pJWnlyTnFic3k2QWxNRkY2MXhIaTJNakIzOXRaTGxiX3pQUFBsZks5SnQtZ1Z5ZzFvQy16WFhETHJQSEtGXzBmcGdIOFhxMW5CX3pOYnJOLXNCS0lZM0dxNlQ3Z2ZSUUU?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Palvella Therapeutics Q1 Earnings Call Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxPbEF5YlZ6N1VyU0VTSGFvNUJuUFhqWjV6bXFHRDBBUE40ZWl5SUwwbkdPc2lzd2ZpUGNlX0gyTk4zRVBpMmY1dTd0eGhWVVA2cGZGYnRSeV9oRGhzb3VEcVdpdElDSk8tRkZ4bGZrWlVFaGFzdXJldlBRdjNOUXk5Vk1qTmZmVnVrdnZ6YS1iaHBhUTF3ZkYtNmRyTGVUYTkzUEJONHNtTHpUYS1IVkdV?oc=5", "source_name": "TradingView", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New Palvella Director Brings Rare Disease Insight To Low Valued Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPZm1QTFY2NGl1UVotTGtFVnd6aWRib3A2OGEwSzVfNjlfczJxTElBdVQxZjd6SU9yM0NGZnFZRTBNcFVvcUVBX2tsOXVZWEdQZU9FVE9saDVmZUNRS19NZkZ2dHV0VmhRVGNLVjlRVjZubG10ZGlrZUFVRC1KLVhzYkxzb0MzcmZIb25NR19pSWJSZUtsdzVzcDJvWTVvaG82MWJERw?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Palvella Hire Highlights QTORIN Launch Plans And Deep Rare Skin Focus", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Palvella raises $230M to develop rare skin disease drugs", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxORVVSVFJacUpIRVVxS3VNMnd6ZWp5SE0yQ1ZsOFNnQmJTNi1IcWZhZTQ3SHg3NTJRMHhJYkhzdFdZZFdqQTFPTWZNODIxNF8yQTQ2NTlsUUdkc1I2a3pHY2xNdnZwY1ZFMlo2Z2Q4S2tKUmVzX3pxMVlXakJMRVZFNFB1MnBfTmc5NkJxNU9pRS1wNENXdkRVZTFhdGlBZjE4ZHctZ19XdFp4UEJCYjEtOENIQkt6Y0xvZlZ0dVJn?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Therapeutics Announces Closing of Upsized Public", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gJBVV95cUxPNWNuXzlJa09MRk9OZmhsOXhPM184M3hzWmtES2JGM3V5TE5LTTZ6N3p1YjgtR2VOOGRUdS1hOG5aemlNakRybkgwQXBrbWFHOTJhekZmMnF5ZFdJQXZRR0Jkb0NSOEVFTDR4REF4NWZVdWxJTElWZF9iaFA0MjBIdlpNWVZtNi1yQVJxd3lMaGl2YkE4b1BXcTIwVElTaW10eTd0RU5yLThnR3RIY05Fa2MzdVMyam9IcVN6SGdGV05SWXpLMmtta2ZBcUNsV2pQekpxNGI1N2w0aXpZUEp3SVdRbU5aX3h6bnZaR0dwOGtJXzZfN1JLdHh0bC03aXVXVlVVOEc2ekZSQng2U2RzdkpHRVh5SzRPUUljczdVVHRVa2VxelR1VVpDUy1DNmk5X2pheUlVRk14ZEFPcVJReXhCTjdRMnNZdXVmeUJPQnJsdw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Therapeutics Closes $230 Million Upsized Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNWGJORFhPOU9MWmYxVGZQcm5nVGRLUVFkMHlVdzRzZElBbTRiLVhXaHlPTzY1ZXdLYzZZS2ExWHZTYTVhQWpmNGdqdk1SeDBBTW1ONFhZd2RKeXNCNHhMbVV2c0lKaXhySmRyWFg0WUVGQ1hwWkd0X2Rabm5IdUx5ZHZiOU5kR2lxUzJwVl9OYzFJYXg0c3o3SXVBMTV5dm5saTcxSThQZlZOaEJJRi1IZzFlU2RXdTQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters\u2019 Option to Purchase Additional Shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNQmFkR1d0Q1I0ZThMOEpqLWNfS1RFTmVZdEh2QlhJUEhsX2FfZWcxek1XZmY0LTc5bkN1a1hkLWhOZmx6VS10bUNvZmJFNzUxSUR4VlBxaDhWbHlKNzVjbjM4NS1mUzc1WjdmR1VGNkFQbnNERXVmQ3VVM2JXeTJ6dVpVcGlRdlVhTTZZLXZQeTVZeFRuX2VSRA?oc=5", "source_name": "Market source", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Therapeutics, Inc. Announces $200 Million Upsized Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxPU0ZXZTRUaDVZNnc5eW03LUVPcmh6MFRIaDFYd3k1WXozQ1NlT2dSajFDRHU3cDNVbXVnSkt6dk51dWZSdW8xcFNpLWtTZTdFVjNJeEJaZ2cxeWlnY2FsVlFTS0s0X2pNWVlGZ0tkMEI1QXJzajFsWjVRNklWLVJKTk9DT0x2UjRlZnBYYjh1V0dzbldmUUI2b0RlbWxqV29CZmNPUTUyZURNaFEtSTFSNllxaWdGRUkzXzRhODVzMG5hNHhNTnc?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Therapeutics price target raised to $255 from $200 at H.C. Wainwright", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxOX2oxS05WMDIzbW1taGJfbVFST2ZzS19nWlpSQ2l1aEZoaXJMUm9PeFdaVTEtTDI0UmRKUUR4NkxxT3RfUWdyVUI4RVg0WFBCZEtrbEUweDNQcTVrSlVOcDdJXzB3Q1ZfRVFXNHdHbFhPY2lJQ1pzM1BFZW53R21DbGRlazJXek5aWnY1SjlIYnE?oc=5", "source_name": "Market source", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Palvella Therapeutics (PVLA) Sees Significant Decline", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxQbnlZN1ZLZVJaNjc4MUJrQUNuRHBDd1dXV0hWeVNOS29kb2xlSk5yMzFNSURTWEZONUhFZDRlaHNDOC1rZVBOV3hRU1NsS0xmVDJqZ2N5V21tSFBXUFh0M3lxcmE4Y0J4dnZTYVBjZkkzMDNmMC1La2lHaHlQQmtVVmVzN2ZfTzBZZW1DaWY4c3FaeTYx?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-20T14:40:08+00:00", "published_display": "20 Jul 2026 14:40", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Therapeutics (PVLA) COO exercises options, then sells 4,302 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNQUsxSl9SSXFFVkd0VW9Bd1FpaHZxUGlmYVdUbDR3SGx6T3RvZHRiZlVMNjdNSFFwazBvV09lbllTZ2hxR3o1Y1lBTkd4ZmI4YnJVZWU3ZkxkMHRDYkFINTc1V2JyX2laQy1XcmRsMGRUV2dQdnpNc0dQc3ltM08zWExmTFZYQ2lscVhkWEw1elR5R29laFRMaGE0X1RtN281dGZrU09nS1Z0RG1HQVZCdDFOb3dGMlIzbElR?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-17T20:05:56+00:00", "published_display": "17 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] PALVELLA THERAPEUTICS, INC. Insider Trading Activity", "summary": "Palvella Therapeutics, Inc.'s Chief Operating Officer, Kathleen Goin, reported exercising and selling 4,302 shares of common stock on July 15, 2026, through a pre-arranged Rule 10b5-1 trading plan. The sales occurred across four transactions at weighted average prices ranging fro", "url": "https://www.stocktitan.net/sec-filings/PVLA/form-4-palvella-therapeutics-inc-insider-trading-activity-43697412446d.html", "source_name": "Stock Titan", "published_at": "2026-07-17T19:40:27", "published_display": "17 Jul 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Therapeutics (PVLA) Submits Initial Module of NDA For QTORIN", "summary": "Palvella Therapeutics (PVLA) has submitted the initial module of its New Drug Application (NDA) to the FDA for QTORIN 3.9% rapamycin anhydrous gel, a treatment for microcystic lymphatic malformations. The company plans to complete the NDA application in the latter half of 2026 an", "url": "https://finance.yahoo.com/healthcare/articles/palvella-therapeutics-pvla-submits-initial-140151901.html", "source_name": "Market source", "published_at": "2026-07-15T13:01:00", "published_display": "15 Jul 2026 13:01", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Therapeutics posts corporate presentation highlighting Phase 3 SELVA wins, NDA rolling review and $262M cash", "summary": "Palvella Therapeutics recently released a corporate presentation detailing positive Phase 3 SELVA results and plans for a potential U.S. launch of QTORIN\u2122 rapamycin for microcystic LMs in the first half of 2027. The company has a strong financial position with $262 million cash a", "url": "https://www.tradingview.com/news/tradingview:5f24f58bec376:0-palvella-therapeutics-posts-corporate-presentation-highlighting-phase-3-selva-wins-nda-rolling-review-and-262m-cash/", "source_name": "TradingView", "published_at": "2026-07-15T10:10:42", "published_display": "15 Jul 2026 10:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Therapeutics (PVLA) Proxy filing Summary", "summary": "Palvella Therapeutics (PVLA) has released a summary of its proxy filing for its annual meeting scheduled for June 10, 2026. Key voting matters include the election of three Class III director nominees, the ratification of Ernst & Young as the independent public accounting firm, a", "url": "https://quartr.com/events/palvella-therapeutics-pvla-proxy-filing_F6m87FdS", "source_name": "Quartr", "published_at": "2026-07-11T07:40:19", "published_display": "11 Jul 2026 07:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Palvella Therapeutics, Inc. \u2013 NASDAQ:PVLA", "summary": "This article provides financial information for Palvella Therapeutics, Inc. (NASDAQ: PVLA), specifically focusing on its price-to-book forward metric. It mentions that market data is provided by ICE Data Services and FactSet, with SEC filings from Quartr. The content appears to b", "url": "https://www.tradingview.com/symbols/NASDAQ-PVLA/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T18:40:21", "published_display": "04 Jul 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors", "summary": "Palvella Therapeutics has announced the appointment of Matt Pauls, J.D., M.B.A., to its Board of Directors. Pauls brings over 25 years of experience in the biopharmaceutical industry, particularly in advancing and commercializing therapies for rare diseases. This appointment come", "url": "https://finance.yahoo.com/healthcare/articles/palvella-therapeutics-appoints-accomplished-rare-113000906.html", "source_name": "Market source", "published_at": "2026-07-04T08:39:22", "published_display": "04 Jul 2026 08:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PVLA - Palvella Therapeutics Inc Volatility & Greeks", "summary": "This article provides a detailed financial overview for Palvella Therapeutics Inc (PVLA), including its last close price, market capitalization, income, sales, and various financial ratios. It also covers performance metrics such as volatility, short interest, analyst recommendat", "url": "https://finviz.com/stock?t=PVLA&ta=1&p=m&ty=ocv&b=2&r=max&ov=chain_strike&s=160", "source_name": "Finviz", "published_at": "2026-07-03T11:10:00", "published_display": "03 Jul 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Therapeutics Adds Industry Veteran to Board", "summary": "Palvella Therapeutics has expanded its Board of Directors by appointing Matthew Pauls, an industry veteran with extensive experience in biopharmaceuticals and rare diseases, as a Class I director. Pauls brings expertise in commercialization, clinical development, and M&A, which i", "url": "https://www.theglobeandmail.com/investing/markets/stocks/PVLA-Q/pressreleases/3075067/palvella-therapeutics-adds-industry-veteran-to-board/", "source_name": "The Globe and Mail", "published_at": "2026-07-02T08:11:31", "published_display": "02 Jul 2026 08:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mizuho Securities Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $240", "summary": "Mizuho Securities has reiterated its Buy rating on Palvella Therapeutics (PVLA.US), maintaining a target price of $240. This indicates a continued positive outlook from the firm regarding the company's stock performance.", "url": "https://www.moomoo.com/news/post/72327093/mizuho-securities-maintains-palvella-therapeutics-pvlaus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-07-02T06:10:00", "published_display": "02 Jul 2026 06:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Therapeutics appoints Matt Pauls to board of directors", "summary": "Palvella Therapeutics has announced the appointment of Matt Pauls to its board of directors, leveraging his 25 years of biopharmaceutical industry experience. Pauls previously held leadership roles at Savara Inc., Strongbridge Biopharma plc, and Insmed Incorporated, and served on", "url": "https://www.investing.com/news/company-news/palvella-therapeutics-appoints-matt-pauls-to-board-of-directors-93CH-4767579", "source_name": "Investing.com", "published_at": "2026-06-30T12:09:00", "published_display": "30 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Therapeutics appoints Matt Pauls to board of directors By Investing.com", "summary": "Palvella Therapeutics has appointed Matt Pauls to its board of directors, leveraging his 25 years of biopharmaceutical industry experience. Pauls, currently chair and CEO of Savara Inc., previously led Strongbridge Biopharma through its Nasdaq IPO and commercialized key therapies", "url": "https://ng.investing.com/news/stock-market-news/palvella-therapeutics-appoints-matt-pauls-to-board-of-directors-93CH-2579864", "source_name": "Investing.com Nigeria", "published_at": "2026-06-30T11:40:20", "published_display": "30 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Therapeutics stock hits 52-week high at 151.36 USD", "summary": "Palvella Therapeutics Inc. (PVLA) has reached a new 52-week high of $151.36, reflecting a 569.92% increase over the past year. Despite its $2.17 billion market capitalization, InvestingPro suggests the stock may be overvalued, although it shows strong momentum. The company recent", "url": "https://www.investing.com/news/company-news/palvella-therapeutics-stock-hits-52week-high-at-15136-usd-93CH-4766063", "source_name": "Investing.com", "published_at": "2026-06-29T20:39:44", "published_display": "29 Jun 2026 20:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella submits FDA NDA for QTORIN gel", "summary": "Palvella Therapeutics (NASDAQ:PVLA) has submitted the first module of its rolling New Drug Application (NDA) to the FDA for QTORIN 3.9% rapamycin gel. This treatment is for microcystic lymphatic malformations, a rare condition affecting over 30,000 patients in the U.S. The compan", "url": "https://grafa.com/en/news/united-states/palvella-qtorin-rapamycin-gel-fda-nda-submission", "source_name": "grafa.com", "published_at": "2026-06-29T17:26:00", "published_display": "29 Jun 2026 17:26", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN\u2122 Rapamycin for the Treatment of Microcystic Lymphatic Malformations", "summary": "Palvella Therapeutics has submitted the first module of its rolling New Drug Application (NDA) to the FDA for QTORIN\u2122 rapamycin, aimed at treating microcystic lymphatic malformations (microcystic LMs). The company expects to complete the NDA submission in the second half of 2026 ", "url": "https://uk.finance.yahoo.com/news/palvella-therapeutics-submits-first-module-113000891.html", "source_name": "Market source", "published_at": "2026-06-29T11:12:43", "published_display": "29 Jun 2026 11:12", "sentiment": "positive", "sentiment_pct": 71, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Therapeutics Submits First Rolling NDA Module for QTORIN Rapamycin in Microcystic Lymphatic Malformations", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxOb0p2UzZFWE5LTGtZZUdXeEJSdlZKY0hZZkNweEVBd1lrVGpyLUFWbXpRamdrTHVOOEQxX0hoWlhqRGtRSi1sZjdFYjhzN2tkMUNsQTVxdm9XNnc3Skx1T0RwUUFtQTY0VFFRc3NLc3FNTHdtOUJmYkhhcEhldTF3aGRYTlhWRWRfNlpBa3F0WE9xdWYxUU1vVWVXWDdqdnV5NVNocl9BWjQtS0MxLWVEc05LX2NpMEZBUmRyT21maDZZUmc3ZGRkTWl0dFZKcDZGdGpOS3VUXzF6Q19pblMxUw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What to Know About This $476,000 Palvella Therapeutics Insider Sale After a 620% Stock Rally", "summary": "", "url": "https://finance.yahoo.com/m/734dcfb8-e453-35d9-a1cd-ebde9185c0a0/what-to-know-about-this.html", "source_name": "Motley Fool", "published_at": "2026-06-27T16:31:54+00:00", "published_display": "27 Jun 2026 16:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PVLA - Palvella Therapeutics Inc Short Interest", "summary": "This article provides comprehensive financial data for Palvella Therapeutics Inc (PVLA), including its short interest, market capitalization, earnings, sales figures, and various financial ratios. It also details insider and institutional ownership, performance metrics across dif", "url": "https://finviz.com/stock?t=PVLA&ty=si&ta=1&p=d", "source_name": "Finviz", "published_at": "2026-06-26T16:40:20", "published_display": "26 Jun 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Palvella Therapeutics, Inc. \u2013 NASDAQ:PVLA", "summary": "This article provides limited information on the \"Price to earnings forward\" metric for Palvella Therapeutics, Inc. (NASDAQ: PVLA), indicating a period value, change, and percentage change. The content, which appears to be from TradingView, does not include actual financial figur", "url": "https://www.tradingview.com/symbols/NASDAQ-PVLA/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T13:40:40", "published_display": "26 Jun 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Therapeutics, Inc. Actuals & Estimates (NASDAQ:PVLA)", "summary": "This article provides an overview of Palvella Therapeutics, Inc. (PVLA) stock performance, financial actuals, and analyst estimates. Key information includes the current stock price, historical highs and lows, market capitalization, upcoming earnings reports, and revenue and net ", "url": "https://www.tradingview.com/symbols/NASDAQ-PVLA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T12:40:02", "published_display": "26 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Palvella Therapeutics, Inc. \u2013 NASDAQ:PVLA", "summary": "The article discusses the enterprise value to EBIT forward for Palvella Therapeutics, Inc. (NASDAQ: PVLA). It appears to be a stub or a section from a larger financial analysis platform, providing a title and indicating that the content would detail this financial metric. The pla", "url": "https://www.tradingview.com/symbols/NASDAQ-PVLA/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T00:39:29", "published_display": "26 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Therapeutics, Inc. Actuals & Estimates (LS:A40RA6)", "summary": "This article provides financial actuals and estimates for Palvella Therapeutics, Inc. (LS:A40RA6), including analyst opinions, historical price data, volatility, market capitalization, and upcoming earnings dates. It highlights that analysts estimate A40RA6's price to range from ", "url": "https://www.tradingview.com/symbols/LS-A40RA6/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T18:39:29", "published_display": "25 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Therapeutics Insiders Placed Bullish Bets Worth US$850.0k", "summary": "The article reports that insiders at Palvella Therapeutics recently made bullish investments, purchasing shares valued at US$850,000. These significant insider buys often signal confidence in the company's future prospects and are closely watched by investors as a potential indic", "url": "https://www.moomoo.com/news/post/72041442/palvella-therapeutics-insiders-placed-bullish-bets-worth-us-850-0k", "source_name": "Moomoo", "published_at": "2026-06-25T14:40:03", "published_display": "25 Jun 2026 14:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Palvella Therapeutics, Inc. \u2013 LS:A40RA6", "summary": "This article provides financial information for Palvella Therapeutics, Inc. (A40RA6) on TradingView. It shows that the market is closed with no trades and displays the \"Price to earnings forward\" value and period. The content is primarily a data page rather than a descriptive art", "url": "https://www.tradingview.com/symbols/LS-A40RA6/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T14:39:29", "published_display": "25 Jun 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CCORF Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $227", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNVWstZ2x4VW11ak9mM0ZHc1VjaWFsZE1mS2EzMjJWdmxnRHd6aHJsOFFuc1RZbWIzWnB5enhPMnl2ZGVzd2VkajBkY2lVRUR5a2ZrR2JEY253R2luVlFDNTJXX0lVR2xqOWdfb3piM1VJMDBfSGF6a1dOb0c2dUZIbnc4S19KMkVVTVRhOHZTZkZFa2VHdUtJa0h6VVdFOHhra0pId055TXJVanNVYWdCRmhSWWhZOVZlWTYw?oc=5", "source_name": "Moomoo", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Palvella Therapeutics, Inc. \u2013 NASDAQ:PVLA", "summary": "This article provides the \"Price to sales forward\" metric for Palvella Therapeutics, Inc. (NASDAQ: PVLA). It appears to be a financial data snippet from TradingView, offering a specific valuation ratio for the company without additional commentary or analysis. The content primari", "url": "https://www.tradingview.com/symbols/NASDAQ-PVLA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-24T15:09:29", "published_display": "24 Jun 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Palvella Therapeutics, Inc. \u2013 LS:A40RA6", "summary": "This article provides financial information for Palvella Therapeutics, Inc. (A40RA6) on TradingView, specifically focusing on its forward price-to-book value. It details the company's financial overview, news, and community discussions, all hosted on the TradingView platform whic", "url": "https://www.tradingview.com/symbols/LS-A40RA6/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-24T14:09:29", "published_display": "24 Jun 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Therapeutics COO Kathleen Goin sells $476,372 in stock By Investing.com", "summary": "Kathleen Goin, COO of Palvella Therapeutics (NASDAQ:PVLA), sold 4,302 shares worth $476,372 on June 17, 2026. This sale followed the acquisition of shares through stock option exercises valued at $34,883 and was executed under a Rule 10b5-1 trading plan. Despite the sale, the sto", "url": "https://za.investing.com/news/stock-market-news/palvella-therapeutics-coo-kathleen-goin-sells-476372-in-stock-93CH-4338777", "source_name": "Investing.com South Africa", "published_at": "2026-06-23T02:40:40", "published_display": "23 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Therapeutics COO Kathleen Goin sells $476,372 in stock", "summary": "Kathleen Goin, COO of Palvella Therapeutics (NASDAQ:PVLA), sold 4,302 shares of PVLA stock valued at $476,372 on June 17, 2026, after exercising stock options worth $34,883. The transactions were conducted under a Rule 10b5-1 trading plan. Following the sales, Ms. Goin holds no d", "url": "https://www.investing.com/news/insider-trading-news/palvella-therapeutics-coo-kathleen-goin-sells-476372-in-stock-93CH-4754022", "source_name": "Investing.com", "published_at": "2026-06-22T21:10:12", "published_display": "22 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Therapeutics granted FDA rolling review for QTORIN", "summary": "The FDA has granted Palvella Therapeutics a rolling review for its rare genetic disease drug candidate, QTORIN rapamycin. This treatment targets microcystic lymphatic malformations, a condition affecting approximately 30,000 individuals in the US with no other approved therapies.", "url": "https://grafa.com/en/news/united-states/palvella-therapeutics-qtorin-fda-rolling-review", "source_name": "grafa.com", "published_at": "2026-06-22T16:10:12", "published_display": "22 Jun 2026 16:10", "sentiment": "positive", "sentiment_pct": 86, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella shares advance after FDA grants rolling review for rare disease therapy", "summary": "Palvella shares are advancing after the FDA granted a rolling review for its rare disease therapy. A rolling review allows a drug company to submit sections of its New Drug Application (NDA) to the FDA as they are completed, rather than waiting for all sections to be finalized. T", "url": "https://www.msn.com/en-us/health/other/palvella-shares-advance-after-fda-grants-rolling-review-for-rare-disease-therapy/ar-AA26g2s9", "source_name": "MSN", "published_at": "2026-06-22T14:12:05", "published_display": "22 Jun 2026 14:12", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Therapeutics' Qtorin Granted FDA Rolling Review; Shares Rise Pre-Bell", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/palvella-therapeutics-apos-qtorin-granted-122601831.html", "source_name": "MT Newswires", "published_at": "2026-06-22T12:26:01+00:00", "published_display": "22 Jun 2026 12:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Grants Rolling Review of Palvella\u2019s QTORIN\u2122 Rapamycin NDA for Microcystic Lymphatic Malformations", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/fda-grants-rolling-review-palvella-113000180.html", "source_name": "GlobeNewswire", "published_at": "2026-06-22T11:30:00+00:00", "published_display": "22 Jun 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is Palvella Therapeutics stock rallying today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPZ1VObkxNcFdRMkpOWXFYalBXNTNkWDRCV2hGR0sxR2VaWjYtVkhLdzM1SHlKUG1KMmdTUDBBLWVXUU91MmJkUFFxNDVUWjQ3dHYzRnlFX1V2Z3N2dDZtZFN4SmYwNXA4OHJfSVk5S3UzZ0RLRWl0RWpqc2hVZ0h0RG9jdWs4anlqY1hkMld1S1k5b3NwWFZVMHhUQjhYTG94SEFGLTNySERVWUhwaTdnVQ?oc=5", "source_name": "Investing.com", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Therapeutics Announces FDA Rolling Review for QTORIN Rapamycin NDA in Microcystic Lymphatic Malformations", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxOeVdvdVlFcm9CT1ZjZXdRWVdMMnJiNVFteFdLeERScjJ6ZGNXX2phRlBfN0V3OENMM2FadUVMSjhfV2Y0VXlmaE1MZkxiRlpDa1lBMW1UUm1Sd3l4MDJxTGlxNUV3T0R5aHJXNlFhNTRkOWd2eXlMbXcxU00yWVIyZkoxUlJRdDB5LUlyRVFxbENvcXQ5bTNuT0FvcjNEZ3ZOVWliNmRreWFST2M4aEFGZmV1NkpqRXQ0TTBrT3dYTWRWdWVaMHd5eE1nU2dVYUJDZzFxU29oWWM3ZDZ0R2pXQw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Therapeutics (PVLA) Stock Valuation Check After Strong Recent Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPbFpaanNtVUFNU0ZFWlFOV0F5bWVaQTQycnd6SHJEaFNRaElOTVJYZ1l5ajItLW5kSVRENnJwMTI2UWp6WVVYRGVxMVdYNlJCVmNCREg5VXVCSkE5VHlzYVpqcDc5VzZFWVJiOFRUMk9WYkJPejE5MVpaaHVsQTlSNXYyVjRNeVJVWlpXUy0tblRwV3ZhbzRuQUpuRFM2cUdXSTBaRXJoTFVaNFE?oc=5", "source_name": "Market source", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Palvella Therapeutics (PVLA) Valuation After A Strong 1-Year Run And Recent Share Price Pullback", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Therapeutics: Qtorin Continues Making Progress, So I Remain Bullish", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQVEF2OV82U29kS3drYjU4NXdJZ3hXeEdhZlBPWF9YT2R0Y0FEWTVIRmtkWDNRbm1YQjZYTDJzVGtjN0NOZXE3cm1xWHdWdUpQQ1VMTFBPMlBVY2xUS1dLZHdkZkdMMGhnNklHWUo1RDhTSE1aRjM3Qms3amROaENQX2ZXZjAtQVNJVUNIX3ljUXdNblBxZXdnakJsOThKZzJyVzJ0bEJFZVZBc0JP?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Therapeutics Says No Additional Efficacy Study Planned for Qtorin Rapamycin", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/palvella-therapeutics-says-no-additional-121708814.html", "source_name": "MT Newswires", "published_at": "2026-06-03T12:17:08+00:00", "published_display": "03 Jun 2026 12:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN\u2122 Rapamycin in Microcystic Lymphatic Malformations", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/palvella-therapeutics-announces-completion-fda-113000899.html", "source_name": "GlobeNewswire", "published_at": "2026-06-03T11:30:00+00:00", "published_display": "03 Jun 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Prognosis For Palvella Therapeutics (NASDAQ:PVLA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxQd0hNNDBUdE5SZ2NXU2lMcjItOHdqYlhBMGdqLWItM0pJWnlyTnFic3k2QWxNRkY2MXhIaTJNakIzOXRaTGxiX3pQUFBsZks5SnQtZ1Z5ZzFvQy16WFhETHJQSEtGXzBmcGdIOFhxMW5CX3pOYnJOLXNCS0lZM0dxNlQ3Z2ZSUUU?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Therapeutics Q1 Earnings Call Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxPbEF5YlZ6N1VyU0VTSGFvNUJuUFhqWjV6bXFHRDBBUE40ZWl5SUwwbkdPc2lzd2ZpUGNlX0gyTk4zRVBpMmY1dTd0eGhWVVA2cGZGYnRSeV9oRGhzb3VEcVdpdElDSk8tRkZ4bGZrWlVFaGFzdXJldlBRdjNOUXk5Vk1qTmZmVnVrdnZ6YS1iaHBhUTF3ZkYtNmRyTGVUYTkzUEJONHNtTHpUYS1IVkdV?oc=5", "source_name": "TradingView", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New Palvella Director Brings Rare Disease Insight To Low Valued Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPZm1QTFY2NGl1UVotTGtFVnd6aWRib3A2OGEwSzVfNjlfczJxTElBdVQxZjd6SU9yM0NGZnFZRTBNcFVvcUVBX2tsOXVZWEdQZU9FVE9saDVmZUNRS19NZkZ2dHV0VmhRVGNLVjlRVjZubG10ZGlrZUFVRC1KLVhzYkxzb0MzcmZIb25NR19pSWJSZUtsdzVzcDJvWTVvaG82MWJERw?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Hire Highlights QTORIN Launch Plans And Deep Rare Skin Focus", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella raises $230M to develop rare skin disease drugs", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxORVVSVFJacUpIRVVxS3VNMnd6ZWp5SE0yQ1ZsOFNnQmJTNi1IcWZhZTQ3SHg3NTJRMHhJYkhzdFdZZFdqQTFPTWZNODIxNF8yQTQ2NTlsUUdkc1I2a3pHY2xNdnZwY1ZFMlo2Z2Q4S2tKUmVzX3pxMVlXakJMRVZFNFB1MnBfTmc5NkJxNU9pRS1wNENXdkRVZTFhdGlBZjE4ZHctZ19XdFp4UEJCYjEtOENIQkt6Y0xvZlZ0dVJn?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Therapeutics Announces Closing of Upsized Public", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gJBVV95cUxPNWNuXzlJa09MRk9OZmhsOXhPM184M3hzWmtES2JGM3V5TE5LTTZ6N3p1YjgtR2VOOGRUdS1hOG5aemlNakRybkgwQXBrbWFHOTJhekZmMnF5ZFdJQXZRR0Jkb0NSOEVFTDR4REF4NWZVdWxJTElWZF9iaFA0MjBIdlpNWVZtNi1yQVJxd3lMaGl2YkE4b1BXcTIwVElTaW10eTd0RU5yLThnR3RIY05Fa2MzdVMyam9IcVN6SGdGV05SWXpLMmtta2ZBcUNsV2pQekpxNGI1N2w0aXpZUEp3SVdRbU5aX3h6bnZaR0dwOGtJXzZfN1JLdHh0bC03aXVXVlVVOEc2ekZSQng2U2RzdkpHRVh5SzRPUUljczdVVHRVa2VxelR1VVpDUy1DNmk5X2pheUlVRk14ZEFPcVJReXhCTjdRMnNZdXVmeUJPQnJsdw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Therapeutics Closes $230 Million Upsized Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNWGJORFhPOU9MWmYxVGZQcm5nVGRLUVFkMHlVdzRzZElBbTRiLVhXaHlPTzY1ZXdLYzZZS2ExWHZTYTVhQWpmNGdqdk1SeDBBTW1ONFhZd2RKeXNCNHhMbVV2c0lKaXhySmRyWFg0WUVGQ1hwWkd0X2Rabm5IdUx5ZHZiOU5kR2lxUzJwVl9OYzFJYXg0c3o3SXVBMTV5dm5saTcxSThQZlZOaEJJRi1IZzFlU2RXdTQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters\u2019 Option to Purchase Additional Shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNQmFkR1d0Q1I0ZThMOEpqLWNfS1RFTmVZdEh2QlhJUEhsX2FfZWcxek1XZmY0LTc5bkN1a1hkLWhOZmx6VS10bUNvZmJFNzUxSUR4VlBxaDhWbHlKNzVjbjM4NS1mUzc1WjdmR1VGNkFQbnNERXVmQ3VVM2JXeTJ6dVpVcGlRdlVhTTZZLXZQeTVZeFRuX2VSRA?oc=5", "source_name": "Market source", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Therapeutics, Inc. Announces $200 Million Upsized Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxPU0ZXZTRUaDVZNnc5eW03LUVPcmh6MFRIaDFYd3k1WXozQ1NlT2dSajFDRHU3cDNVbXVnSkt6dk51dWZSdW8xcFNpLWtTZTdFVjNJeEJaZ2cxeWlnY2FsVlFTS0s0X2pNWVlGZ0tkMEI1QXJzajFsWjVRNklWLVJKTk9DT0x2UjRlZnBYYjh1V0dzbldmUUI2b0RlbWxqV29CZmNPUTUyZURNaFEtSTFSNllxaWdGRUkzXzRhODVzMG5hNHhNTnc?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Palvella Therapeutics price target raised to $255 from $200 at H.C. Wainwright", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxOX2oxS05WMDIzbW1taGJfbVFST2ZzS19nWlpSQ2l1aEZoaXJMUm9PeFdaVTEtTDI0UmRKUUR4NkxxT3RfUWdyVUI4RVg0WFBCZEtrbEUweDNQcTVrSlVOcDdJXzB3Q1ZfRVFXNHdHbFhPY2lJQ1pzM1BFZW53R21DbGRlazJXek5aWnY1SjlIYnE?oc=5", "source_name": "Market source", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 100, "total_relevant": 62, "sentiment_summary": {"positive": 21, "negative": 2, "neutral": 39, "score": 57, "total": 62, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 83, "events": [{"event": "general", "label": "Market update", "weight": 22.15, "count": 39}, {"event": "earnings", "label": "Earnings", "weight": 7.56, "count": 16}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 21, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 157.24, "latest_week": "2026-07-17", "one_week_move": 8.6, "four_week_move": 39.0, "twelve_week_move": 27.2, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.645471, "market_dynamics_buy_signal": false, "relative_strength": 49.935167, "fair_value_gap": 131.8, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 58.5693, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+8.6% over one week, +39.0% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 67, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 13}, {"label": "TradingView", "count": 11}, {"label": "Investing.com", "count": 4}, {"label": "Quiver Quantitative", "count": 4}, {"label": "simplywall.st", "count": 4}, {"label": "Stock Titan", "count": 3}, {"label": "Moomoo", "count": 3}, {"label": "GlobeNewswire", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 53}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 39}, {"label": "Earnings", "count": 16}, {"label": "Analyst action", "count": 4}, {"label": "Deals and strategy", "count": 2}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "57/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "83/100 classification confidence."}, {"label": "Company focus", "value": "53", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+8.6% over one week, +39.0% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Negative", "tone": "negative", "text": "Palvella Therapeutics (PVLA) Sees Significant Decline"}], "updated_at": "2026-07-21T00:51:25.855389+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}